CJC 1004

Drug Profile

CJC 1004

Alternative Names: CCI 1004; DAC:T1; DAC:Thrombin inhibitor

Latest Information Update: 16 Aug 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ConjuChem Biotechnologies
  • Class Antithrombotics
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 16 Aug 2002 Discontinued - Phase-I for Thrombosis in USA (Intra-arterial)
  • 27 May 2002 Phase-I clinical trials in Thrombosis in USA (Intra-arterial)
  • 29 Jan 2002 ConjuChem has announced a sponsored research agreement with Almirall Prodesfarma in Spain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top